NASDAQ NMS - GLOBAL MARKET · DNLI
-0.12% · -$0.0300 · Vol 681.0K
Market closed · last close 4:00 PM ET · price as of 16:00:58 ET
Denali Therapeutics Inc

Denali Therapeutics Inc

Biotechnology
$24.92
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Analyst data unavailable at compute time
DNLI
Denali Therapeutics Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

36/ 100
Veridion Score
SELL BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is DNLI moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading DNLI catalysts
About Denali Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2017
Employees
507
Country
US

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$25.25
Day high
$25.37
Day low
$24.60
Previous close
$24.95
52W high
$27.21
-8.42% from high
52W low
$12.75
84% of range
Market cap
$4B
EPS
$-2.8300
Beta
0.58
Shares out
159.8M
Volume
681K
0.44× rel vol
Avg volume
1.6M
VWAP
$24.91
Price history computed in-house
1W
+2.34%
1M
+7.83%
3M
+28.59%
1Y
+60.88%
YTD
+50.94%
SMA 50 $24.32 · above
SMA 200 $20.46 · above
52W position 84%

DNLI overview

Veridion Score
36
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around DNLI.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading DNLI Form 4 filings
Public disclosures

Congress activity in DNLI

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for DNLI in the cached public ledger.

Federal contracts

DNLI contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for DNLI in this window.
Lobbying spend

DNLI lobbying filings, year to date.

Registered lobbying filings matched to Denali Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for DNLI in this window.
Loading news for DNLI
Analyst ratings
Sovereign unlock shows live analyst consensus for DNLI.
Options
Sovereign unlock shows live options positioning for DNLI.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.